Search

everythinglearnresearchcommunity

for

Search:↓

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

A gel of keratin microspheres promotes hair follicle growth, showing similar effectiveness to minoxidil in mice. The treatment activates hair growth pathways and reduces inflammation, with potential applications in drug delivery for hair-related disorders.

RU58841 cured seborrheic dermatitis, oily scalp, dandruff, and scalp pain, improving hair health when combined with Minoxidil. Another user noted diet impacts their seborrheic dermatitis and that finasteride hasn't changed their condition.

Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.

A 24-year-old has been using finasteride, oral minoxidil, and microneedling for hair loss. They reduced minoxidil due to heartburn and are considering a hair transplant.

The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.

The user is exploring hair loss treatments in China, currently using finasteride and minoxidil, and is concerned about seborrheic dermatitis. Clinics are recommending selenium sulfide, doxycycline, and mesotherapy ampoules like PT88/PT66 or SP88/SP66, but the user is unsure about their effectiveness.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

The conversation is about using RF microneedling with ExoHealer, along with finasteride and minoxidil, to improve hair thickness and reduce shedding. The user reports noticeable improvements in scalp texture and oiliness, with plans to consider stem cell treatments in the future.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

RCH-01's progress is uncertain, and there's skepticism about its effectiveness. Users are losing hope in this treatment.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

Hair loss treatments, with users discussing their experiences with both RU58841 and Pyrilutamide, noting that the latter has only recently become available but may yield better results in the long term.

Mixing Nizoral and T-Gel in a 1:1 ratio and using it three times a week provided relief from persistent seborrheic dermatitis. This treatment is recommended for those with stubborn SD.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.

A user switched from finasteride to dutasteride, experiencing significant shedding initially but noticing improved hair health and thickness over time. They also use minoxidil, both oral and topical, and report no significant side effects from the treatments.

A user is seeing good results with RU58841 for hair loss, noting reduced shedding and thicker hair. They plan to use pumpkin seed oil as a solvent to avoid water content, which they believe reduces the effectiveness of anti-androgens.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A 23-year-old male noticed hair loss and started using finasteride 1mg, initially experiencing significant shedding which reduced after 100 days. He switched from the brand Andropel to Folcres due to availability in Argentina.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.